Logo image of ALSEN.PA

SENSORION SA (ALSEN.PA) Stock Fundamental Analysis

EPA:ALSEN - Euronext Paris - Matif - FR0012596468 - Common Stock - Currency: EUR

0.57  -0.01 (-2.4%)

Fundamental Rating

3

Taking everything into account, ALSEN scores 3 out of 10 in our fundamental rating. ALSEN was compared to 72 industry peers in the Biotechnology industry. While ALSEN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALSEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALSEN had negative earnings in the past year.
In the past year ALSEN has reported a negative cash flow from operations.
In the past 5 years ALSEN always reported negative net income.
In the past 5 years ALSEN always reported negative operating cash flow.
ALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

ALSEN's Return On Assets of -23.31% is in line compared to the rest of the industry. ALSEN outperforms 55.56% of its industry peers.
With a decent Return On Equity value of -28.36%, ALSEN is doing good in the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
ROA -23.31%
ROE -28.36%
ROIC N/A
ROA(3y)-44.22%
ROA(5y)-35.53%
ROE(3y)-68.9%
ROE(5y)-62.72%
ROIC(3y)N/A
ROIC(5y)N/A
ALSEN.PA Yearly ROA, ROE, ROICALSEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

ALSEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALSEN.PA Yearly Profit, Operating, Gross MarginsALSEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ALSEN has been increased compared to 1 year ago.
The number of shares outstanding for ALSEN has been increased compared to 5 years ago.
The debt/assets ratio for ALSEN has been reduced compared to a year ago.
ALSEN.PA Yearly Shares OutstandingALSEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ALSEN.PA Yearly Total Debt VS Total AssetsALSEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 5.16 indicates that ALSEN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.16, ALSEN belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
ALSEN has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
ALSEN has a Debt to Equity ratio of 0.02. This is amongst the best in the industry. ALSEN outperforms 80.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 5.16
ROIC/WACCN/A
WACCN/A
ALSEN.PA Yearly LT Debt VS Equity VS FCFALSEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

ALSEN has a Current Ratio of 6.92. This indicates that ALSEN is financially healthy and has no problem in meeting its short term obligations.
ALSEN has a better Current ratio (6.92) than 90.28% of its industry peers.
ALSEN has a Quick Ratio of 6.92. This indicates that ALSEN is financially healthy and has no problem in meeting its short term obligations.
ALSEN's Quick ratio of 6.92 is amongst the best of the industry. ALSEN outperforms 90.28% of its industry peers.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.92
ALSEN.PA Yearly Current Assets VS Current LiabilitesALSEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.96% over the past year.
EPS 1Y (TTM)63.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 29.09% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 116.73% on average over the next years. This is a very strong growth
EPS Next Y58.14%
EPS Next 2Y18.78%
EPS Next 3Y11.12%
EPS Next 5Y29.09%
Revenue Next Year299.94%
Revenue Next 2Y85%
Revenue Next 3Y26.42%
Revenue Next 5Y116.73%

3.3 Evolution

ALSEN.PA Yearly Revenue VS EstimatesALSEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M
ALSEN.PA Yearly EPS VS EstimatesALSEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALSEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSEN.PA Price Earnings VS Forward Price EarningsALSEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSEN.PA Per share dataALSEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.78%
EPS Next 3Y11.12%

More info and screens

0

5. Dividend

5.1 Amount

ALSEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSORION SA

EPA:ALSEN (3/7/2025, 7:00:00 PM)

0.57

-0.01 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-18 2024-09-18
Earnings (Next)03-12 2025-03-12/amc
Inst Owners50.29%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap171.28M
Analysts86.67
Price Target2.42 (324.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.05
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.31%
ROE -28.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.22%
ROA(5y)-35.53%
ROE(3y)-68.9%
ROE(5y)-62.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.92
Quick Ratio 6.92
Altman-Z 5.16
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)202.41%
Cap/Depr(5y)136.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.84%
EPS Next Y58.14%
EPS Next 2Y18.78%
EPS Next 3Y11.12%
EPS Next 5Y29.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year299.94%
Revenue Next 2Y85%
Revenue Next 3Y26.42%
Revenue Next 5Y116.73%
EBIT growth 1Y-9.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.83%
EBIT Next 3Y-20.63%
EBIT Next 5Y31.28%
FCF growth 1Y-55.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.15%
OCF growth 3YN/A
OCF growth 5YN/A